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Supplementary Methods 
Demographics Split by Age 
Each diagnostic group (control, MCI and AD) was split into two groups by the median age (75 years). 
For each age group the mean demographic factors were reported (see table 1).  
Grey Matter Volume change without correction for APOE e4 and WMH 
(model 2) 
GM volume change (outcome) was investigated with a main effect of group, a linear interaction term 
between group and baseline age, and with TIV as a covariate. See main paper for more information. 
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White Matter Volume change with correction for APOE e4 and WMH (model 
3) 
WM volume change was also investigated, with a main effect of group, a linear interaction term 
between group and baseline age, and with WMH, APOE e4 allele presence and TIV as a covariate. 
See main paper for more information. 
White Matter Volume change without correction for APOE e4 and WMH 
(model 4) 
WM volume change was also investigated, with a main effect of group, a linear interaction term 
between group and baseline age, and TIV as a covariate. See main paper for more information. 
Regression of Baseline Brain Volume and Age 
Brain volumes were estimated from the 1.5T volumetric T1-weighted images using a multi atlas 
template brain segmentation method (Leung et al., 2011). 
To analyse the cross-sectional relationship between baseline brain volume and age at baseline a 
multiple linear regression was performed with baseline brain volume as the outcome, age as the 
predictor variable, and diagnosis and TIV as covariates. See supplementary table 2 for results. 
Analyses in CSF confirmed dataset 
 CSF data was collected in a subset of ADNI participants (n=352), using a previously 
described method (Shaw et al., 2009). We classified patients by amyloid status using the abeta 1-42 
cut off of 192pg/ml (Shaw et al., 2009); controls were selected for analysis if they were abeta negative 
(>192pg/ml) and MCI and AD patients selected if abeta positive (<192pg/ml). The final subset for 
analysis was 270 participants (see supplementary figure 3).  
 VBM steps were completed as per the pipeline described in the main paper section 2.2.1 until 
the DARTEL stage, in which the DARTEL registration was limited to the subset with CSF data (n= 
270). The volume change maps of the subset were aligned to this CSF specific template.  
The main model of GM change with age as a predictor was run in this CSF subset, WMH, TIV and 
APOE status (presence/absence of an e4 allele) were used as covariates, see the main paper for 
more details regarding the model (model 1, section 2.2.1). Models of BSI in this subset were also 
fitted in the CSF subset, as in main paper (section 2.2.2).  
Relationships between age and cognition 
 We fitted multilevel linear mixed-effects regression models for repeated measures of MMSE 
(Frost et al., 2004). Interval in years between baseline and follow up was included as a fixed effect, in 
order that the resulting coefficient represented change in MMSE per year (outcome). The following 
covariates were included as main effects and as interaction terms with interval, in order that their 
inclusion could affect mean MMSE and how this changed over time: diagnostic group, an interaction 
between baseline age and diagnostic group, WMH, and APOE e4 carrier status (presence/absence of 
an e4 allele). Participant-level random effects for intercept and time since baseline MMSE 
measurement were included to permit between-participant heterogeneity in baseline MMSE and in 
rate of change in MMSE. Different random intercept and slope terms were fitted for control, MCI and 
AD groups, as the variability in MMSE is often higher in AD patients. In MCI and AD groups 
unstructured covariance of the random effects was used to allow for a correlation between baseline 
MMSE and rate of change in MMSE. A separate residual variance was fitted for each diagnostic 
group.  
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 After estimation, the difference in the age effect on MMSE (baseline and change) for controls 
was subtracted from that in MCI/AD in order to account for normal aging. 
Analyses using age at onset 
For AD patients, age at symptom onset was calculated by subtracting the year of estimated symptom 
onset from the date of the baseline visit, in order to give years since AD onset. Year of estimated 
symptom onset was estimated by the study partner, the individual accompanying the patient to visits, 
with 10 hours or more contact per week with the patient. Years since AD onset was then subtracted 
from the patient’s baseline age to give age at onset. 
Relationships between baseline age and atrophy rate, or age at onset and atrophy rate, were run in 
ADs only (as there is no equivalent for variable for age at onset for controls). Four AD participants 
were excluded as there was no year of AD onset information. Analyses were run to estimate change 
in GM, predicted by either age at baseline or age-at-onset, see main paper section 2.2.1 model 1, 
adjusted for APOE (presence/absence of an e4 allele), WMH and TIV and for multiple comparisons 
after bootstrapping, family wise error correction (p<0.05). Results using age at onset and results using 
baseline age were qualitatively compared. 
Linearity analyses 
To examine the concept of non-linearity in the age relationship a quadratic term was added to the 
models of GM change predicted by age for BSI and VBM (age*age*diagnostic group), (main paper 
model 1, section 2.2.1). Models were adjusted for WMH, age and TIV. The outcome of the non-linear 
term investigated whether the effect of age on atrophy rates differed for a 10 year increase in age. 
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 Demographics table split by mean age 
Supplementary Table 1: Subject demographics and basic imaging information, split by mean age 
(75 years) in each diagnostic group. Values are mean (SD) unless reported. Years since AD symptom 







 Controls MCI AD 
 75 and under Over 75 75 and under Over 75 75 and under Over 75 
N 91 100 163 176 74 79 
Age at baseline, years  71.7 (2.7) 79.7 (3.6) 68.9 (4.8) 80.7 (3.4) 68.5 (4.9) 81.0 (3.9) 
Percentage male 53 51 59 66 54 54 
MMSE at baseline, /30 29.1 (1.1) 29.2 (0.9) 27.1 (1.8) 26.8 (1.7) 23.6 (1.8) 23.2 (2.0) 
Length of follow up, years 2.6 (0.7) 2.6 (0.8) 2.3 (0.8) 2.3 (0.8) 1.6 (0.64) 1.7 (0.60) 
Min., max. length of follow up, 
years 
0.5, 3.4 0.5, 3.7 0.5, 3.5 0.5, 3.4 0.5, 2.6 0.5, 3.0 
BSI measurements per subject, 
No., 
3.3 (0.8) 3.2 (1.0) 3.6 (1.3) 3.5 (1.3) 2.2 (0.8) 2.4 (0.7) 
Total brain volume, ml 1084 (106) 1054 (97) 1096 (111) 1025 (107) 1038 (123) 1009 (105) 
Total hippocampal volume, ml 5.41 (0.73) 5.00 (0.65) 4.71 (0.85) 4.22 (0.77) 4.14 (0.92) 3.72 (0.83) 
Total intracranial volume, ml 1446 (127) 1446 (142) 1481 (141) 1451 (148) 1443 (176) 1455 (151) 
White Matter Hyperintensity, ml 0.17 (0.4) 0.25 (0.5) 0.17 (0.4) 0.40 (0.7) 0.31 (0.6) 0.54 (1.1) 
log2WMH, ml -2.75 (2.4) -2.06 (2.2) -2.73 (2.4) -1.50 (2.1) -1.71 (2.3) -1.07 (2.1) 
Percentage APOE e4 carriers 25 29 66 47 76 65 
Percentage Hypertensive 36 49 47 53 45 58 
Percentage Diabetic 5 6 9 5 3 9 
Percentage Hypercholesteraemic 29 23 29 31 32 39 
Years of education 15.7 (2.5) 16.3 (3.13) 15.8 (3.0) 15.6 (3.0) 14.7 (3.3) 14.9 (2.9) 
Years since AD symptom onset N/A N/A N/A N/A 3.4 (2.4) 3.7 (2.7) 
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Supplementary Table 2: Results from the regression model assessing the relationship between 
cross-sectional brain volume and age. Estimates are shown for difference in brain volume (ml) with (p 
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Supplementary Figure 1: Results of the F Test to test the age-group interaction term to predict 
volume change (A). Clusters in the images represent voxels in which there is a significant difference 
in the relationship between age and atrophy rate across the three groups. Results of the T tests to 
directly compare the age*group interaction between controls and AD patients (B). Clusters indicate 
regions in which the relationships between age and atrophy are different between groups.  Red 
clusters in the control vs AD comparison signify regions in which there is greater atrophy at younger 
ages in ADs, whilst for controls there is little age-atrophy relationship. Blue clusters indicate voxels 
which expand more at younger ages in ADs, whilst controls expand more at older ages. There were 
no differences between control and MCI patients. Analyses are corrected for multiple comparisons, 
FWE p<0.05, and TIV. 
GM volume change; differences in age-diagnostic group interaction without 
correction for WMH or APOE genotype 
  
A. Between all groups (F test of age*group interaction) 





 Age*group interaction for grey matter volume change without correction for WMH 
and APOE genotype (model 2) 
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WM volume change; differences in age-diagnostic group interaction  
  
Supplementary Figure 2: Results of the F Test to test the age-group interaction term to predict white 
matter volume change corrected for WMH and APOE genotype (presence/absence of an APOE e4 
allele) (1a, model 3), and uncorrected (1b, model 4). Clusters in the images represent voxels in which 
there is a significant difference in the relationship between age and atrophy rate across the three 
groups. Results of the T tests to directly compare atrophy-age relationship between controls and AD 
patients corrected for APOE and WMH (2a, model 3) and uncorrected (2b, model 4). Clusters indicate 
regions in which the relationships between age and atrophy are different between groups. There were 
no differences between control and MCI patients. All analyses are corrected for multiple comparisons, 
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Supplementary Figure 3; Flowchart 
showing the selection of subjects for 
analysis based on CSF abeta 1-42 
status. 
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CSF confirmed VBM results  
Supplementary Figure 4: Results of an age-by-group interaction between controls and AD patients 
in the subset with confirmed abeta 1-42 status (no amyloid pathology in controls and confirmed 
amyloid pathology in AD) (a) and the full dataset (b).Clusters indicate regions in which the 
relationships between age and atrophy are different between groups, i.e. differences in age-by-group 
interaction.  Red clusters signify regions in which there is greater atrophy at younger ages in AD 
patients, whilst for controls there is little age-atrophy relationship. Analyses are corrected for multiple 
comparisons, FWE p<0.05, and are also corrected for APOE genotype (presence/absence of an e4 




a) CSF subset results (n=270) 
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CSF confirmed BSI results 

















































Supplementary Table 3: Results from the regression model assessing the relationship between 
change in brain and hippocampal volume (left and right summed) and age by each diagnostic group 
(estimated using an age-by-diagnostic group interaction) in the subset with abeta status confirmed by 
CSF. Average brain and hippocampal atrophy rates with (p value) and 95% confidence intervals [95% 
CI] are shown in ml/year. Age interaction estimates (a) represent an increase in atrophy rate for a ten 
year increase in baseline age (ml/year/decade), adjusted for total intracranial volume, APOE 
genotype (presence/absence of an e4 allele)  and WMH volume. For MCI and AD groups, age 
interaction estimates are given after subtraction of the estimate effect in controls (to account for 
normal aging), p values for MCI and AD indicate whether the age-atrophy relationship is significantly 
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Relationships between age and cognition  
  
  















































Supplementary Table 4: Results from a regression model investigating the effect of baseline age on 
change in MMSE (outcome). Estimates are shown for an increase in atrophy rate (ml/year) with (p 
values) and [95% confidence intervals] for a 10 year increase in age. Models are adjusted for total 
intracranial volume, APOE status (presence/absence of an e4 allele) and WMH. 
Age at onset VBM comparison  
 
Supplementary Figure 5: VBM results showing the effect of age on GM change in AD patients using 
the variable baseline age (a), or age at onset (b). Red clusters signify regions in which there is greater 
atrophy at younger ages in AD patients, blue clusters indicate regions which expand more at younger 
ages. Analyses are corrected for multiple comparisons, FWE p<0.05 and are additionally corrected for 






b) Age at onset and volume change 
a) Baseline age and volume change 
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Age at onset BSI comparison 

































Supplementary Table 5: Results from a regression model investigating the effect of baseline age or 
age at onset on atrophy rates (outcome) in AD patients. Estimates are shown for an increase in 
atrophy rate (ml/year) with (p values) and [95% confidence intervals] for a 10 year increase in age. 
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Supplementary Table 6: Results from a regression model investigating a non-linear effect of age 
(predictor) on atrophy rates (outcome). Estimates are shown for an increase in atrophy rate (ml/year), 
(p value), and [95% confidence intervals]: a 10 year increase in age (constant age effect)
a
, for a 
change in slope of the age-atrophy rate relationship for a 10 year increase in baseline age (quadratic 
age effect)
b
. Models are adjusted for age, total intracranial volume, presence/absence of an APOE e4 
allele and WMH. 
 
Linearity Relationships  
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